David Risinger
Stock Analyst at Leerink Partners
(3.54)
# 895
Out of 5,001 analysts
171
Total ratings
64.84%
Success rate
13.96%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $458 → $456 | $391.64 | +16.43% | 5 | Sep 25, 2025 | |
| MTSR Metsera | Downgrades: Market Perform | $77 → $57 | $52.33 | +8.92% | 2 | Sep 24, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $18 → $22 | $15.13 | +45.41% | 5 | Sep 18, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $185.42 | -17.48% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $562.27 | +48.33% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $231.54 | -11.03% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $45.10 | +61.86% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $15.69 | +339.77% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $7.61 | +110.25% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $19.23 | +128.81% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $36.02 | +324.76% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $14.60 | -31.51% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $30.62 | +53.49% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $282.20 | +12.69% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $24.25 | -54.64% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $763.00 | -39.97% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $73.34 | -42.73% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $111.00 | -18.02% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $25.48 | +88.38% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $10.68 | +246.44% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $131.80 | +33.54% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $9.90 | +61.62% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $22.27 | +102.07% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.45 | +442.64% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $20.14 | +103.57% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $146.32 | +18.92% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $35.28 | +44.56% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $20.20 | -60.40% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $83.93 | +6.04% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $10.01 | -70.03% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $30.00 | -46.67% | 9 | Apr 2, 2020 |
Vertex Pharmaceuticals
Sep 25, 2025
Upgrades: Outperform
Price Target: $458 → $456
Current: $391.64
Upside: +16.43%
Metsera
Sep 24, 2025
Downgrades: Market Perform
Price Target: $77 → $57
Current: $52.33
Upside: +8.92%
Roivant Sciences
Sep 18, 2025
Maintains: Outperform
Price Target: $18 → $22
Current: $15.13
Upside: +45.41%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $185.42
Upside: -17.48%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $562.27
Upside: +48.33%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $231.54
Upside: -11.03%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $45.10
Upside: +61.86%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $15.69
Upside: +339.77%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $7.61
Upside: +110.25%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $19.23
Upside: +128.81%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $36.02
Upside: +324.76%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $14.60
Upside: -31.51%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $30.62
Upside: +53.49%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $282.20
Upside: +12.69%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $24.25
Upside: -54.64%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $763.00
Upside: -39.97%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $73.34
Upside: -42.73%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $111.00
Upside: -18.02%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.48
Upside: +88.38%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $10.68
Upside: +246.44%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $131.80
Upside: +33.54%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $9.90
Upside: +61.62%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $22.27
Upside: +102.07%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.45
Upside: +442.64%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $20.14
Upside: +103.57%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $146.32
Upside: +18.92%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $35.28
Upside: +44.56%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $20.20
Upside: -60.40%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $83.93
Upside: +6.04%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $10.01
Upside: -70.03%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $30.00
Upside: -46.67%